North American results vs intent-to-treat population from the ECHELON-1 trial
Chapter 3In this video, board-certified hematologist and medical oncologists, Scott Smith, MD, PhD, FACP of Loyola University Medical Center and William Harwin, MD of Florida Cancer Specialists, discuss a pre-specified analysis of efficacy and safety of Adcetris (A) + AVD vs ABVD in North America and the results of Dr. Ramachandren's 2018 ASCO abstract on brentuximab vedotin plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma: North American results (Abstract #/ Poser* # 7541/178:).
Bleomycin-induced lung toxicity in Hodgkin lymphoma patients
In this video, board-certified hematologist and medical oncologists, Scott Smith, MD, PhD, FACP of Loyola University Medical Center and William Harwin, MD of Florida Cancer Specialists, discuss bleomycin-induced lung toxicity in Hodgkin lymphoma patients and the results of Dr. Morris' 2018 ASCO abstract on pulmonary events in patients with Hodgkin lymphoma after frontline chemotherapy in the US Department of Defense healthcare system (Abstract # e2770).
Concomitant administration of G-CSF prophylaxis with Adcetris (A) + AVD
In this video, board-certified hematologist and medical oncologists, Scott Smith, MD, PhD, FACP of Loyola University Medical Center and William Harwin, MD of Florida Cancer Specialists, discuss concomitant administration of G-CSF prophylaxis with A + AVD and the results of Dr. Straus' 2018 ASCO abstract on improving outcomes with brentuximab vedotin plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (Abstract/Poster #: 7534/171).
